12.07.2015 Views

PRODUCT MONOGRAPH IMITREX DF IMITREX ... - GlaxoSmithKline

PRODUCT MONOGRAPH IMITREX DF IMITREX ... - GlaxoSmithKline

PRODUCT MONOGRAPH IMITREX DF IMITREX ... - GlaxoSmithKline

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

unaltered when preceded by a single clinical dose of the nasal decongestantxylometazoline (Otrivin ®2 ).Ergot-Containing Drugs: Ergot-containing drugs have been reported to cause prolongedvasospastic reactions. Because there is a theoretical basis for these effects being additive,ergot-containing or ergot-type medications (like dihydroergotamine or methysergide) arecontraindicated within 24 hours of <strong>IMITREX</strong> <strong>DF</strong> ® or <strong>IMITREX</strong> ® administration (seeCONTRAINDICATIONS).MAO Inhibitors: In studies conducted in a limited number of patients, MAO inhibitorsreduce sumatriptan clearance, significantly increasing systemic exposure. Therefore, theuse of <strong>IMITREX</strong> <strong>DF</strong> ® or <strong>IMITREX</strong> ® in patients receiving MAO inhibitors iscontraindicated (see CONTRAINDICATIONS and ACTION AND CLINICALPHARMACOLOGY).Selective Serotonin Reuptake Inhibitors (SSRIs)/Serotonin Norepinephrine ReuptakeInhibitors (SNRIs): Cases of life-threatening serotonin syndrome have been reportedduring combined use of selective serotonin reuptake inhibitors (SSRIs) or serotoninnorepinephrine reuptake inhibitors (SNRIs) and triptans (see WARNINGS ANDPRECAUTIONS).Other 5-HT 1 agonists: The administration of <strong>IMITREX</strong> <strong>DF</strong> ® or <strong>IMITREX</strong> ® with other5-HT 1 agonists has not been evaluated in migraine patients. As an increased risk ofcoronary vasospasm is a theoretical possibility with coadministration of 5-HT 1 agonists,use of these drugs within 24 hours of each other is contraindicated.Drug - Laboratory Interactions<strong>IMITREX</strong> <strong>DF</strong> ® and <strong>IMITREX</strong> ® are not known to interfere with commonly employedclinical laboratory tests.DOSAGE AND ADMINISTRATIONDosing ConsiderationsAdults:<strong>IMITREX</strong> <strong>DF</strong> ® and <strong>IMITREX</strong> ® are indicated for the acute treatment of migraineheadache with or without aura. Sumatriptan should not be used prophylactically.Sumatriptan may be given orally, subcutaneously or as a nasal spray. The safety oftreating an average of more than four headaches in a 30-day period has not beenestablished. The recommended dose of <strong>IMITREX</strong> <strong>DF</strong> ® and <strong>IMITREX</strong> ® should notbe exceeded.2 Trademark Ciba Self MedicationOctober 21, 2014Page 17 of 58

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!